CDK17

CDK17 (cyclin-dependent kinase 17), also known as PCTAIRE2, belongs to the PCTAIRE subfamily of cyclin-dependent serine/threonine kinases and is predominantly expressed in terminally differentiated neurons, supporting a specialized role distinct from canonical cell-cycle CDKs^[1]. Mechanistically, CDK17 participates in neuronal signaling networks and has been associated with protein interaction complexes linked to neuronal differentiation and intracellular regulatory processes^[1][2]. In disease-related models, increased PCTAIRE2 expression has been reported in amyloid precursor protein (APP)-dependent experimental systems and has been associated with Alzheimer-related molecular pathology, suggesting relevance to neurodegenerative signaling pathways rather than classical proliferative cell-cycle control^[3]. Compared with related PCTAIRE family members, including CDK16 and CDK18, CDK17 remains substantially less characterized, and current evidence highlights its neuronal enrichment as a distinguishing biological feature^[4]. For experimental research applications, CDK17 is primarily investigated through expression profiling, protein-interaction studies, and neurodegeneration-associated cellular models, whereas selective CDK17-targeted pharmacological inhibitors have not been well established in the published literature cited here^[1][3][4].